Basis: Trailing twelve months (TTM net income over TTM revenue). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the net profit margin high or low?
The net profit margin of -689.20% is 245% below its 4-year average of -200.00%, near the low end of its 4-year range (-1847.68%–10693.39%).
144.18% below its 12-month average of 1560.07%.
Reported quarterly profit margin; no daily interpolation. Q2 FY2026 (2026-06-30): 10693.39%.
NET PROFIT MARGIN
-689.20%
NET PROFIT MARGIN AVG TTM
1560.07%
NET PROFIT MARGIN AVG 3Y
-176.17%
NET PROFIT MARGIN AVG 5Y
N/A
NET PROFIT MARGIN AVG 10Y
N/A
NET PROFIT MARGIN AVG 15Y
N/A
NET PROFIT MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
-144.18%
CURRENT VS 3Y AVG
-291.22%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
-0.26%
median of 863 covered companies
CURRENT VS SECTOR MEDIAN
-264976.92%
vs the sector median at left
Metagenomi, Inc. Common Stock
Market Cap
$39.15M
Net Profit Margin
-689.20%
TTM Avg
1560.07%
3Y Avg
-176.17%
5Y Avg
N/A
Market Cap
$38.77M
Net Profit Margin
-11.86%
TTM Avg
-39.34%
3Y Avg
-22.53%
5Y Avg
-16.34%
Market Cap
$39.80M
Net Profit Margin
0.00%
TTM Avg
-111.93%
3Y Avg
-252.09%
5Y Avg
-173.47%
Market Cap
$38.25M
Net Profit Margin
8.38%
TTM Avg
3.43%
3Y Avg
-19.55%
5Y Avg
-29.01%
Market Cap
$37.75M
Net Profit Margin
0.00%
TTM Avg
-27258.72%
3Y Avg
-52085.61%
5Y Avg
-35139.97%
Market Cap
$40.59M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
0.00%
Market Cap
$37.45M
Net Profit Margin
-65.31%
TTM Avg
-147.78%
3Y Avg
-3852.20%
5Y Avg
-3378.36%
Market Cap
$41.86M
Net Profit Margin
-4.42%
TTM Avg
-14.19%
3Y Avg
-49.13%
5Y Avg
-77.93%
Market Cap
$36.70M
Net Profit Margin
0.00%
TTM Avg
0.00%
3Y Avg
0.00%
5Y Avg
-322.60%
| NAME | MARKET CAP | NET PROFIT MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Metagenomi, Inc. Common Stock (MGX) | $39.15M | -689.20% | 1560.07% | -176.17% | N/A |
| Harvard Bioscience, Inc. (HBIO)vs › | $38.77M | -11.86% | -39.34% | -22.53% | -16.34% |
| Veru Inc. (VERU)vs › | $39.80M | 0.00% | -111.93% | -252.09% | -173.47% |
| Nephros, Inc. (NEPH)vs › | $38.25M | 8.38% | 3.43% | -19.55% | -29.01% |
| Incannex Healthcare Limited (IXHL)vs › | $37.75M | 0.00% | -27258.72% | -52085.61% | -35139.97% |
| Filana Therapeutics, Inc. (FLNA)vs › | $40.59M | 0.00% | 0.00% | 0.00% | 0.00% |
| QT Imaging Holdings, Inc. (QTI)vs › | $37.45M | -65.31% | -147.78% | -3852.20% | -3378.36% |
| Precipio, Inc. (PRPO)vs › | $41.86M | -4.42% | -14.19% | -49.13% | -77.93% |
| Edesa Biotech, Inc. (EDSA)vs › | $36.70M | 0.00% | 0.00% | 0.00% | -322.60% |
| EUDA Health Holdings Limited (EUDA)vs › | $36.04M | -40.49% | -211.76% | -338.86% | -222.41% |
Operating Margin
-380.9%
Net Profit Margin
-689.2%
Net Profit Margin = Net Income / Revenue
Net profit margin is the percentage of revenue that becomes net income after all expenses, taxes, and interest.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | NET PROFIT MARGIN |
|---|---|
| 2026-06-30 | 10693.39% |
| 2026-03-31 | -1847.68% |
| 2025-12-31 | -576.02% |
| 2025-09-30 | -235.51% |
| 2025-06-30 | -233.85% |
| 2025-03-31 | -606.71% |
| 2024-12-31 | -243.37% |
| 2024-09-30 | -163.04% |
| 2024-06-30 | -53.67% |
| 2024-03-31 | -225.36% |
| 2023-12-31 | -155.61% |
| 2023-09-30 | -160.32% |
| 2023-06-30 | -114.74% |
| 2023-03-31 | -186.36% |
| 2022-12-31 | -261.43% |
| 2022-09-30 | -211.30% |
| 2022-06-30 | -277.72% |
| 2022-03-31 | -277.72% |
